MedTrace Logo

Clinical and Genetic Characterization of Individuals With Achromatopsia

NCT01846052 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 56

Last updated 2017-10-13

No results posted yet for this study

Summary

The purpose of this study is to identify individuals with achromatopsia caused by mutations in the CNGB3 gene and characterize their clinical condition using several tests of visual function every 6 months for up to 1.5 years.

Conditions

  • Achromatopsia

Sponsors & Collaborators

  • National Eye Institute (NEI)

    collaborator NIH

  • Beacon Therapeutics

    lead INDUSTRY

Principal Investigators

  • Matt Feinsod, MD · Applied Genetics Technologies Corporation

Eligibility

Min Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2017-04-30
Completion
2017-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01846052 on ClinicalTrials.gov